Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 5/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820578 | 0.92 | DRD2 (0.63) | DRD2DRD3JAK2JAK1TYK2 | |
| SCHEMBL2820760 | 0.89 | DRD2 (0.69) | DRD2DRD3JAK2JAK1TYK2 | |
| SCHEMBL2821574 | 0.87 | DRD2 (0.54) | DRD2DRD3JAK2JAK1TYK2 | |
| SCHEMBL2820697 | 0.86 | DRD2 (0.57) | DRD2DRD3ACHEPRKAA2HTR2B | |
| SCHEMBL2819939 | 0.86 | DRD2 (0.55) | DRD2DRD3ACHEPRKAA2HTR2B | |
| SCHEMBL27759410 | 0.85 | DRD2 (0.45) | DRD2DRD3JAK2JAK1TYK2 | |
| SCHEMBL2819916 | 0.85 | DRD2 (0.54) | DRD2DRD3ACHEPRKAA2CCNK | |
| SCHEMBL2821443 | 0.84 | DRD2 (0.53) | DRD2DRD3JAK2JAK1JAK3 | |
| SCHEMBL2819124 | 0.83 | PRKAA2 (0.56) | DRD2DRD3ACHEPRKAA2SSTR5 | |
| SCHEMBL2820003 | 0.83 | DRD2 (0.53) | DRD2DRD3ACHEDRD4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466153-B2 | Piperidinylamino-pyridazines and their use as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-06-18 | — | — | US | disclosed |
| EP-2091938-B1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN-CILAG S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| EP-2091938-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008068277-A1 | PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076187-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | DRD2 1/4885DRD3 8/4885JAK2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.